EE369 Cost-Effectiveness Analysis of Pembrolizumab as a Second-Line Therapy for Advanced Urothelial Carcinoma in the United States
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.635
https://www.valueinhealthjournal.com/article/S1098-3015(23)03765-8/fulltext
Title :
EE369 Cost-Effectiveness Analysis of Pembrolizumab as a Second-Line Therapy for Advanced Urothelial Carcinoma in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03765-8&doi=10.1016/j.jval.2023.09.635
First page :
Section Title :
Open access? :
No
Section Order :
10127